Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 2
2011 7
2012 4
2013 8
2014 17
2015 8
2016 6
2017 10
2018 3
2019 3
2020 2
2021 2
2022 1
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Results by year

Filters applied: . Clear all
Page 1
Abiraterone-Induced Endocrinopathies.
Decamps S, Lis R, Ekanayake P. Decamps S, et al. JCEM Case Rep. 2023 Apr 13;1(2):luad039. doi: 10.1210/jcemcr/luad039. eCollection 2023 Mar. JCEM Case Rep. 2023. PMID: 37908462 Free PMC article.
Abiraterone, a CYP17A1 inhibitor, is used along with prednisone in patients with castration-resistant and castration-sensitive prostate cancer, yielding improved overall and disease-free survival. ...
Abiraterone, a CYP17A1 inhibitor, is used along with prednisone in patients with castration-resistant and castration-sensitive …
CYP17A1 inhibitors in castration-resistant prostate cancer.
Gomez L, Kovac JR, Lamb DJ. Gomez L, et al. Steroids. 2015 Mar;95:80-7. doi: 10.1016/j.steroids.2014.12.021. Epub 2015 Jan 3. Steroids. 2015. PMID: 25560485 Free PMC article. Review.
As such, treatments with novel hormonal agents that specifically target the biochemical conversion of cholesterol to testosterone have come to the forefront. The use of cytochrome P450c17 (CYP17A1) inhibitor underlies one of the most recent advances in the treatment …
As such, treatments with novel hormonal agents that specifically target the biochemical conversion of cholesterol to testosterone have come …
The CYP17A1 inhibitor abiraterone exhibits estrogen receptor agonist activity in breast cancer.
Capper CP, Larios JM, Sikora MJ, Johnson MD, Rae JM. Capper CP, et al. Breast Cancer Res Treat. 2016 May;157(1):23-30. doi: 10.1007/s10549-016-3774-3. Epub 2016 Apr 15. Breast Cancer Res Treat. 2016. PMID: 27083183
As such, inhibition of CYP17A1 is a target for inhibiting the growth of hormone-dependent cancers including prostate and breast cancer. Abiraterone, is a first in class potent and selective CYP17A1 inhibitor that has been approved for the treatment of castration-res …
As such, inhibition of CYP17A1 is a target for inhibiting the growth of hormone-dependent cancers including prostate and breast cancer. Abir …
Preclinical assessment of Orteronel(®), a CYP17A1 enzyme inhibitor in rats.
Zainuddin M, Vinod AB, Gurav SD, Police A, Kumar A, Mithra C, Dewang P, Kethiri RR, Mullangi R. Zainuddin M, et al. Eur J Drug Metab Pharmacokinet. 2016 Feb;41(1):1-7. doi: 10.1007/s13318-014-0229-2. Epub 2014 Oct 9. Eur J Drug Metab Pharmacokinet. 2016. PMID: 25297456
Molecular pathways: Inhibiting steroid biosynthesis in prostate cancer.
Ferraldeschi R, Sharifi N, Auchus RJ, Attard G. Ferraldeschi R, et al. Clin Cancer Res. 2013 Jul 1;19(13):3353-9. doi: 10.1158/1078-0432.CCR-12-0931. Epub 2013 Mar 7. Clin Cancer Res. 2013. PMID: 23470964 Free PMC article. Review.
Preclinical evidence that androgen biosynthesis in prostate cancer cells does not necessarily follow a single dominant pathway, and residual androgens or alternative ligands (including administered glucocorticoids) can reactivate androgen receptor signaling, supports cotargeting …
Preclinical evidence that androgen biosynthesis in prostate cancer cells does not necessarily follow a single dominant pathway, and residual …
Steroid 17-hydroxylase and 17,20-lyase deficiencies, genetic and pharmacologic.
Auchus RJ. Auchus RJ. J Steroid Biochem Mol Biol. 2017 Jan;165(Pt A):71-78. doi: 10.1016/j.jsbmb.2016.02.002. Epub 2016 Feb 6. J Steroid Biochem Mol Biol. 2017. PMID: 26862015 Free PMC article. Review.
The most severe mutations in the cognate CYP17A1 gene abrogate all activities and cause combined 17-hydroxylase/17,20-lyase deficiency (17OHD), a biochemical phenotype that is replicated by treatment with the potent CYP17A1 inhibitor abiraterone acetate. The adrenal …
The most severe mutations in the cognate CYP17A1 gene abrogate all activities and cause combined 17-hydroxylase/17,20-lyase deficiency (17OH …
HSD3B1 and Response to a Nonsteroidal CYP17A1 Inhibitor in Castration-Resistant Prostate Cancer.
Almassi N, Reichard C, Li J, Russell C, Perry J, Ryan CJ, Friedlander T, Sharifi N. Almassi N, et al. JAMA Oncol. 2018 Apr 1;4(4):554-557. doi: 10.1001/jamaoncol.2017.3159. JAMA Oncol. 2018. PMID: 29049452 Free PMC article.
EXPOSURES: Extragonadal androgen ablation with the nonsteroidal CYP17A1 inhibitor ketoconazole among men with metastatic CRPC. MAIN OUTCOMES AND MEASURES: The primary end points of analysis were duration of ketoconazole therapy and time to disease progression strati …
EXPOSURES: Extragonadal androgen ablation with the nonsteroidal CYP17A1 inhibitor ketoconazole among men with metastatic CRPC. …
Human steroid biosynthesis for the oncologist.
Auchus ML, Auchus RJ. Auchus ML, et al. J Investig Med. 2012 Feb;60(2):495-503. doi: 10.2310/JIM.0b013e3182408567. J Investig Med. 2012. PMID: 22222232 Free PMC article. Review.
Since then, AIs have become first-line adjuvant therapy for ER breast cancer in postmenopausal women.In late 2010, a trial comparing abiraterone acetate (a 17-hydroxylase/17,20-lyase [CYP17A1] inhibitor) plus prednisone versus prednisone alone in men with castration …
Since then, AIs have become first-line adjuvant therapy for ER breast cancer in postmenopausal women.In late 2010, a trial comparing abirate …
61 results